National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Send to Printer
Rectal Cancer Treatment (PDQ®)     
Last Modified: 10/26/2009
Health Professional Version
Changes to This Summary (10/26/2009)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Stage IV and Recurrent Rectal Cancer 1

Added text 2 about the Crystal Study that randomly assigned patients to FOLFIRI with or without cetuximab (cited Van Cutsem et al. as reference 47 and level of evidence 1iiDii).

Added text 3 about patients with mutant KRAS tumors who may experience worse outcome when cetuximab is added to multiagent chemotherapy regimens containing bevacizumab.


Table of Links

1http://www.cancer.gov/cancertopics/pdq/treatment/rectal/HealthProfessional/92.c
dr#Section_92
2http://www.cancer.gov/cancertopics/pdq/treatment/rectal/HealthProfessional/481.
cdr#Section_481
3http://www.cancer.gov/cancertopics/pdq/treatment/rectal/HealthProfessional/482.
cdr#Section_482